HOUSTON--(BUSINESS WIRE)--At its annual shareholder meeting held last week, Introgen Therapeutics, Inc.’s (NASDAQ:INGN) shareholders re-elected William H. Cunningham, Ph.D. and S. Malcolm Gillis, Ph.D. who join John N. Kapoor, Charles E. Long, Peter Barton Hutt and David G. Nance as members of the Introgen board of directors. The Introgen board elected David G. Nance to serve as its Chairman. Mr. Nance also serves as President and Chief Executive Officer of Introgen. In addition, Introgen appointed directors for its subsidiary Gendux Pharmaceuticals, Ltd., established to develop and commercialize molecular therapies in Europe.
